Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmalink AB Strengthens Senior Management Team

Published: Thursday, February 21, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Dr. Heather Cook appointed director of regulatory affairs and Marek Poszepczynski as director of business development.

Pharmalink AB has announced that it has appointed Dr. Heather Cook as Director of Regulatory Affairs and Mr. Marek Poszepczynski as Director of Business Development.

Dr. Cook brings to Pharmalink over 15 years of experience within the pharmaceutical industry, with a proven track record in global regulatory affairs and clinical development.

Prior to joining Pharmalink, Dr. Cook was Head of Department for Regulatory Development Projects at H. Lundbeck A/S.

She was also Global Regulatory Affairs Director, Oncology for Astra Zeneca and held a number of other senior roles including Scientific Director for Neuroscience and Infection.

She has worked in the UK, Canada, and Denmark and currently resides in Stockholm. Dr. Cook is also Partner, Pharma and Biotech R&D consultant at PharmaView Consulting HB.

She has a PhD in Zoology from the University of Toronto and is completing an MBA at Stockholm School of Economics.

Marek Poszepczynski joins Pharmalink after a career spanning 10 years and combining financial and business development experience.

Before joining Pharmalink, Mr. Poszepczynski was lead equity analyst at Handelsbanken covering European and Swedish biotechnology stocks.

Prior to Handelsbanken, Mr. Poszepczynski was Vice President of Business Development at Karolinska Development, where he carried out a wide variety of tasks including streamlining the company’s business operations as well as taking part in M&A, licensing and fund raising negotiations.

Mr. Poszepczynski spent six years at BioVitrum AB where he was Director of Corporate Development, and part of the in-and-out licensing deals team of the company’s R&D portfolio.

Mr. Poszepczynski holds a Master of Industrial Engineering and Business Management from KTH Royal Institute of Technology, Stockholm.

Pharmalink’s Managing Director Johan Häggblad said, “These appointments add significant talent and new experience to Pharmalink’s management team as the Company continues to drive forward its late stage clinical development programs for Nefecon® and Busulipo™ and actively seeks new product opportunities. It is a measure of our reputation that such high caliber executives have joined us and I look forward to working with Heather and Marek through what is an exciting stage of development.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmalink Initiates Phase IIb Trial with Nefecon®
Pharmalink expects to announce top line results in the first half of 2015.
Friday, December 21, 2012
Pharmalink Enters Manufacturing Agreement for Nefecon®
Company has entered into a contract with Patheon.
Thursday, November 01, 2012
Pharmalink AB Raises SEK 35 Million through Share Issue
New funds used to further advance Nefecon® and Busulipo™.
Friday, January 06, 2012
Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program
Pharmalink also acquires equipment and technologies from Archimedes Pharma to manufacture TARGIT capsules for Nefecon.
Wednesday, December 14, 2011
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!